The role of HDAC3 in inflammation: mechanisms and therapeutic implications.
| Autor: | Watson N; Department of Pharmacology and Toxicology, Medical College of Georgia, Augusta University, Augusta, GA, United States., Kuppuswamy S; Department of Pharmacology and Toxicology, Medical College of Georgia, Augusta University, Augusta, GA, United States., Ledford WL; Department of Pharmacology and Toxicology, Medical College of Georgia, Augusta University, Augusta, GA, United States., Sukumari-Ramesh S; Department of Pharmacology and Toxicology, Medical College of Georgia, Augusta University, Augusta, GA, United States. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Frontiers in immunology [Front Immunol] 2024 Jul 10; Vol. 15, pp. 1419685. Date of Electronic Publication: 2024 Jul 10 (Print Publication: 2024). |
| DOI: | 10.3389/fimmu.2024.1419685 |
| Abstrakt: | Histone deacetylases (HDACs) are critical regulators of inflammatory gene expression, and the efficacy of pan-HDAC inhibitors has been implicated in various disease conditions. However, it remains largely unclear how HDACs precisely regulate inflammation. To this end, evaluating the isoform-specific function of HDACs is critical, and the isoform-specific targeting could also circumvent the off-target effects of pan-HDAC inhibitors. This review provides an overview of the roles of HDAC3, a class I HDAC isoform, in modulating inflammatory responses and discusses the molecular mechanisms by which HDAC3 regulates inflammation associated with brain pathology, arthritis, cardiovascular diseases, lung pathology, allergic conditions, and kidney disorders. The articles also identify knowledge gaps in the field for future studies. Despite some conflicting reports, the selective inhibition of HDAC3 has been demonstrated to play a beneficial role in various inflammatory pathologies. Exploring the potential of HDAC3 inhibition to improve disease prognosis is a promising avenue requiring further investigation. Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision. (Copyright © 2024 Watson, Kuppuswamy, Ledford and Sukumari-Ramesh.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|